308P - A Prospective, Multicenter, Non-Interventional Study to Evaluate Quality of Life in Chinese Postmenopausal Hormone Receptor-Positive Early Breast Cancer Patients During Treatment with Adjuvant Aromatase Inhibitors

Abstract

ABSTRACT Aim: In the past few decades, both doctors and patients have gradually increased awareness of the importance of quality of life (QOL) assessment during treatment. Endocrine therapy is widely used as adjuvant therapy for HR+ early breast cancer. Some studies suggest that treatment with AIs may improve QOL for those patients. To enable Chinese doctors and patients to more clearly understand the relationship AI therapy and QOL, the study was to evaluate QOL of postmenopausal patients with hormone receptor-positive early breast cancer treated with AIs. Methods: The current study was prospective, multicenter, and observational. There was no intent to intervene in current medical practice of the recruited patients. Eligible patients were recruited within seven days of beginning adjuvant treatment with AIs. We used The Functional Assessment of Cancer Therapy - Breast (FACT-B) scale to evaluate QOL of the patients. Data were collected every six months for a total of five times (at baseline and at 6, 12, 18, and 24 months). Results: Patient characteristics Between June 2010 and October 2013, 494 HR+ EBC patients participated in the study. Patients were recruited form 21 centers and the study end date was October 22, 2013. TOI changes in FACT-B total scores from baseline to 24 months There was a 7.51-point increase in patients' mean FACT-B total scores from 90.69 at baseline to 98.72 at 24 months. TOI, EWB and SWB scores at baseline, 6, 12, and 18 months Patients' mean FACT-B total scores at baseline, 6 months, 12 months, and 18 months were 90.69, 94.36, 97.71, and 96.75, respectively. Patients' mean (FACT-B) EWB subscale scores at baseline, 6 months, 12 months, 18 months, and 24 months were 16.32, 16.55, 17.34, 17.47, and 17.85, respectively. Patients' mean (FACT-B) SWB scores at baseline, 6 months, 12 months, 18 months, and 24 months were 18.61, 19.14, 19.35, 18.32, and 18.40, respectively. Conclusions: The study demonstrated significant improvements in long-term QOL of postmenopausal early breast cancer patients at 6, 12, 18, and 24 months after starting AIs treatment. Disclosure: A. Cao and J. Zhang:: The study was sponsored by Astrazeneca. The sponsor has no role in study design, data, collection and analysis, decision to publish, or preparation of the manuscript.